FOXO Technologies Inc. (FOXO)
| Market Cap | 9.00M |
| Revenue (ttm) | 1.34M |
| Net Income (ttm) | -15.17M |
| Shares Out | 13.63M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,119,126 |
| Open | 0.687 |
| Previous Close | 0.690 |
| Day's Range | 0.613 - 0.709 |
| 52-Week Range | 0.130 - 1.300 |
| Beta | 2.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2024 |
About FOXO
FOXO Technologies Inc. develops epigenetic biomarkers technology solutions in the United States. The company applies automated machine learning and artificial intelligence (AI) technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and Bioinformatics services that provides data solutions using AI and machine learning for... [Read more]
Financial Performance
In 2023, FOXO Technologies's revenue was $145,000, a decrease of -71.62% compared to the previous year's $511,000. Losses were -$29.83 million, -68.69% less than in 2022.
Financial StatementsNews
FOXO Technologies Subsidiary, Myrtle Recovery Centers, Receives Two Full Licenses from the Tennessee Department of Mental Health and Substance Abuse Services
MINNEAPOLIS, MN, Aug. 08, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced that its recently acquired subsidiary, Myrtle Recovery Centers, Inc. (“...
FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements
Reaffirms commitment to regaining compliance with the NYSE American continued listing standards Reaffirms commitment to regaining compliance with the NYSE American continued listing standards
FOXO Technologies Inc. Secures Up to $2.8 Million in Senior Notes to Fund Previously Announced Acquisition of Myrtle Recovery Centers, Inc. and Provide Additional Working Capital
MINNEAPOLIS, MN, June 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), today announced that it has secured up to $2.8 million in Senior Notes from a...
FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.
Acquisition expected to be synergistic with FOXO's epigenetic technology in community health and addiction recovery settings as well as contribute significant cash flow Acquisition expected to be syne...
FOXO Technologies Announces Non-Binding Agreement for Potentially Transformative Merger with M2i Global
Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources Proposed Combination to Focus on Securing Our Nation's Supply to Critical Materials and Resources
FOXO Technologies Announces Appointment of Capital Markets Veteran Francis Colt deWolf to the Board of Directors
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (the “Company”), today announced the appointment of Francis Colt deWolf to the Company's Board of Directors. Mr. deWolf III b...
FOXO Technologies Formalizes License Agreement with KR8.ai to Power New Epigenetic Wellness Solutions
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced it has f...
FOXO Technologies On Track to Commence Commercial Rollout of VITHAR™ AI Health Coach in Early 2024
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a business update on the ...
FOXO Technologies Receives Notice from NYSE American Regarding Late Filing of Quarterly Report on Form 10-Q
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, announced that on November 21, 2023, it ...
FOXO Technologies Provides Reminder for Webinar to be Held Today, November 10th at 10 AM Eastern Time, to Unveil VITHAR™ AI Health Coach
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today provided a reminder that it will h...
FOXO Technologies to Unveil VITHAR™ AI Health Coach; Schedules Webinar for Friday, November 10th at 10 AM Eastern Time
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it will host a webi...
FOXO Technologies Expects Class A Common Stock to Resume Trading, Today, November 7, in Connection with 1-for-10 Reverse Stock Split
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of epigenetic biomarker technology, today announced that it expects its Clas...
FOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Company's Epigenetic Data with the Power of AI
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced plans fo...
FOXO Technologies Inc. Announces Reverse Stock Split
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced that its...
FOXO Technologies Completes Strategic Alternatives Review and Outlines Latest Progress Executing Corporate Strategy
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announces it has c...
FOXO Technologies Announces Issue Notification from USPTO for a Patent Leveraging Machine Learning Approaches to Enable the Commercialization of Epigenetic Biomarkers
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today announced that the...
FOXO Technologies™ Interim CEO Mark White Provides Letter to Shareholders Outlining New AI-Enabled Direct-to-Consumer Strategy and Immediate Expense Reductions
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), a leader in the field of commercializing epigenetic biomarker technology, today provided a letter ...
FOXO Technologies Announces Agreement With Atrio Insurance
MINNEAPOLIS, Minn.--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insu...
FOXO Technologies Inc. Announces NYSE American Acceptance of Compliance Plan
MINNEAPOLIS--(BUSINESS WIRE)--On August 29, 2023, FOXO Technologies Inc. (the “Company”) (NYSEAM: FOXO) received a letter (the “Letter”) from NYSE American LLC (“NYSE American”) stating that NYSE Amer...
FOXO Technologies Inc. Announces Receipt of Second Notice of Non-Compliance from NYSE American
MINNEAPOLIS--(BUSINESS WIRE)--On August 16, 2023, FOXO Technologies Inc. (NYSEAM: FOXO) (the “Company”) received a second written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”)...
FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epige...
FOXO Technologies™ Announces Second Quarter 2023 Financial Results
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter e...
FOXO Technologies™ Sets Second Quarter 2023 Business Update Call for Thursday, August 10, 2023 at 3:15 p.m. CT
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in epigenetic biomarker discovery and commercialization, today announced that it will report financial results for the se...
Longevity Biotech Companies GERO and FOXO Technologies™ to Embark on Joint Initiative on Artificial Intelligence and Epigenetic Data to Discover Signatures of Human Health Trajectories
PALO ALTO, Calif. & MINNEAPOLIS, Minn.--(BUSINESS WIRE)--GERO, a leading AI-driven biotechnology company focused on aging and longevity and FOXO Technologies Inc. (NYSEAM: FOXO), a leader in epigeneti...
FOXO Technologies Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis
MINNEAPOLIS--(BUSINESS WIRE)--FOXO Technologies Inc.™ (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today announced the launch of its cutting-edge Bioinform...